#United Kingdom #Oxford #Care Fertility #U-Ploid #egg quality

Enhancing Egg Quality: A Crucial Collaboration

In a groundbreaking announcement, Care Fertility, a premier provider of fertility treatments, has joined forces with U-Ploid Biotechnologies, an innovative biotech company focused on reproductive health. This new research collaboration aims to enhance the quality of eggs in women of advanced maternal age, a critical concern as egg quality tends to diminish with increasing age, often leading to challenges in conception.

The partnership seeks to harness Care Fertility's extensive clinical expertise in the field of reproductive medicine, further bolstered by its impressive track record in achieving high success rates for patients. Professor Alison Campbell, the Chief Scientific Officer at Care Fertility, expressed enthusiasm about this collaboration, emphasizing the importance of supporting women dealing with age-related infertility:

“Advancing knowledge and treatments to support women facing age-related infertility is a priority for Care Fertility, and it’s extraordinary to think that this research could help tackle the most common cause of infertility.”

This alliance is not a fleeting endeavor; it aims to validate novel therapeutics that could significantly change the landscape of fertility treatment. U-Ploid Biotechnologies plans to fast-track the development of its proprietary therapeutic, which has already shown promising preclinical results in combating egg degradation typically seen with age. By leveraging Care Fertility's clinical insights and experience, the project aspires to reach clinical testing phases more swiftly and efficiently.

Dr. Jordan Abdi, Co-founder and CEO of U-Ploid, articulated the optimism surrounding this partnership:

“We are excited to collaborate with Care Fertility as we transition to the next stage of development. This partnership enables us to benefit from the clinical leadership that Care Fertility offers, granting us valuable insights that could refine our therapeutic approaches.”

Both organizations anticipate enrolling patients in their first study later this year, marking a significant step in long-term research efforts to enhance fertility options for older women.

About Care Fertility

Established over 25 years ago, Care Fertility has earned its reputation as the UK's leading fertility treatment provider. The organization is committed to making family-building possible for all individuals, offering a wide range of fertility solutions, including IVF, egg and sperm donation, fertility preservation, and genetic testing. With a network of clinics across the UK and branches in Ireland, Spain, and the United States, Care Fertility champions a compassionate, patient-centered approach anchored in clinical excellence.

About U-Ploid Biotechnologies

U-Ploid is at the forefront of developing innovative reproductive health treatments designed to address age-related fertility decline. The company’s leading program is a first-of-its-kind therapeutic candidate that aims to mitigate natural egg deterioration associated with aging. Co-founded by respected scientists and industry leaders, U-Ploid is dedicated to enhancing IVF outcomes and ensuring wider reproductive opportunities for individuals worldwide.

In an age where fertility solutions are more crucial than ever, this collaboration between Care Fertility and U-Ploid Biotechnologies represents a hopeful stride towards improved reproductive health solutions. With continued research and innovation, the future looks brighter for aspiring parents facing the challenges of age-related infertility.